September 7, 2017 04:29 AM EDT

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug

John Carroll

Editor & Founder

AstraZeneca and Amgen rolled out Phase IIb data on their late-stage drug tezepelumab late on Wednesday, spotlighting some dramatic results for a therapy they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

Zealand Pharma hit with second CRL for glucagon receptor agonist

AI biotech insitro partners with Lilly on metabolic disease drugs

Crinetics’ $500M offering; Boehringer inks deal with macrocycles biotech

Exclusive Q&A: FDA's principal deputy commissioner on taking over for Califf, adcomms, accelerated approvals and more

CMS looks to $2 out-of-pocket cap for some commonly used generic drugs

As­traZeneca, Am­gen whip up some block­buster ex­cite­ment with a pos­si­ble game-chang­ing asth­ma drug

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug